Paul

Dr Paul Brooks is CBO at CN Bio, having joined in 2022. He has over 25 years of experience in building businesses and leading high-performance research, product, marketing, and sales teams to develop and commercialize new biotechnology technologies globally for drug discovery, bioproduction and diagnostics.

Dr Brooks has held senior leadership positions in the USA and the UK, including Head of Business Operations and Managing Director of Horizon Discovery Ltd; Chief Commercial Officer and Executive Board member of Oxford Genetics Ltd; Head of Discovery Research Services at MilliporeSigma (Merck KGaA); and Global Marketing Manager at Sigma-Aldrich Corp. Dr Brooks has a BSc in Biochemistry from the University of Wales, a PhD in Molecular Biology from the University of Manchester Institute of Science and Technology (UMIST), and an MBA from the University of Nottingham Business School.

Audrey

Dr Audrey Dubourg is CN Bio’s Product Manager for the PhysioMimix™ OOC range of microphysiological systems. Prior to joining CN Bio, she worked as a postdoctoral scholar at the University of California – Los Angeles (UCLA), in the US, in the Microbiology, Immunology and Molecular Genetics department. She completed an MSc in microbiology at the University of Montpellier II, followed by a PhD in microbiology/parasitology at the University of East Anglia. Audrey has extensive experience in the disciplines of molecular biology and 3D mammalian cell culture. Since joining CN Bio, she has been actively involved in promoting the benefits of incorporating organ-on-a-chip technology into drug discovery and development workflows.

Brian

Dr Brian Manning – Global Head of Sales, is a PhD-qualified pharmacologist, Brian trained in Ireland, France, and the USA before spending 10 years in Big Pharma drug discovery, where he also completed his MBA. He joined CN Bio Innovations in 2020 and prior to that, had a successful career in delivering rapid sales growth for cutting-edge cell culture companies in the UK and US, specializing in organ-on-chip and spheroid cultures over the last 6 years. Currently based in New Jersey, USA, Dr. Manning holds a PhD from the National University of Ireland an MBA from Rensselaer Polytechnic Institute.

James

James Ferritto is the Western US Sales Manager for CN Bio, based out of the Bay Area. In his role, James supports researchers looking to bring more predictive data to their drug development process. He has a track record of helping scientists identify & implement new technologies to improve research outcomes.  James is excited by the PhysioMimix™ Organ-on-Chip platform since he has experienced how it enables more relevant decision-making in preclinical stages. James holds a BS from Boston University (US).

Anthony

Dr. Anthony Berger is CN-Bio’s US-based Field Application Scientist, providing support for the PhysioMimix™ Organ-on-Chip benchtop platform. Anthony has an extensive research background in 3D cell culture, biomaterials, and microfluidics, focusing on how the microenvironment influences cellular decision-making. He is a proponent of complex 3D in vitro models and desires to decrease the barrier to entry of these technologies. Anthony received his BS from Indiana University (US), PhD from the University of Wisconsin (US), and completed a postdoctoral fellowship at Temple University (US).

Scott

Dr Scott Chilton is the Eastern US Sales Manager for CN Bio, based in Massachusetts, USA.  Scott supports researchers who want to develop safe and effective therapeutics faster and more cost-effectively by adopting solutions that provide physiologically relevant and clinically translatable data.  Scott holds a PhD from Harvard University and a BS from Massachusetts Institute of Technology.